HOME >> BIOLOGY >> NEWS
First analysis of FDA's mifepristone adverse event reports

The abortion drug mifepristone (Mifeprex,TM RU-486), initially touted as a more convenient alternative to surgical abortion, has been linked to serious adverse reactions, including several deaths in otherwise healthy women. In "Analysis of Severe Adverse Events Related to the Use of Mifepristone as an Abortifacient," researchers Margaret M Gary MD and Donna J Harrison MD provide an in-depth study of mifepristone adverse event data gathered through the FDA's Adverse Event Reporting System. Their research is available now at The Annals of Pharmacotherapy Online (www.theannals.com) and will appear in the journal's February issue.

This first published analysis of the FDA's mifepristone reports describes 607 adverse events reported over a 4-year period, including fatalities resulting from bleeding or septic shock. Also reviewed are numerous reports of severe bleeding, infection, unsuccessful termination of pregnancy, and fetal malformations that appeared after failed abortion attempts. Reports also detail ruptured ectopic pregnancies, a potentially fatal condition requiring emergency surgical intervention. Unusual allergic reactions were also noted, which Gary and Harrison suspect may have resulted directly from the drug's mechanism of action.

Prompted by their findings, the authors call for increased research into the allergic and fatal septic reactions associated with mifepristone. They also urge that ultrasound imaging be performed before use of the drug to rule out ectopic pregnancies and propose that a fetal registry be established to track birth defects in mifepristone survivors. Finally, incomplete information in many of the adverse event reports prompts Gary and Harrison to speculate on whether the FDA's Adverse Event Reporting System adequately identifies risks and protects public health.

At least 5 women in the US and Canada are known to have died from septic shock after taking mifepristone. In 200
'"/>

Contact: Stan Lloyd, PharmD
assisted@hwbooks.com
513-793-3555
Annals of Pharmacotherapy
28-Dec-2005


Page: 1 2

Related biology news :

1. First case of successful ovarian tissue transplantation between two, nonidentical sisters
2. First new multiple sclerosis gene found in 30 years
3. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
4. First all-African produced genetically engineered maize is resistant to maize streak virus
5. First baby is born after oocytes were matured in the lab and frozen
6. First confirmed common genetic risk factors for breast cancer
7. First demonstration of new hair follicle generation in an animal model
8. First research to show that diabetes damages DNA in mens sperm and may affect fertility
9. First demonstration of muscle restoration in an animal model of Duchenne muscular dystrophy
10. First systematic study of Chinas one-child policy reveals complexity, effectiveness
11. First international conference on self-healing materials

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/19/2019)... ... November 19, 2019 , ... Project Lifeline – ... Stores (NACDS) Foundation to address substance use disorder (SUD) – will take ... who have led to the program’s effectiveness in preventing and treating opioid abuse in ...
(Date:11/19/2019)... ... 19, 2019 , ... The inaugural Cell & Gene Therapy Day takes place ... one-day event will be chaired by Dr Aiman Shalabi, VP R&D, Cell and Gene ... “We are witnessing significant innovation in cell and gene therapies, and we are at ...
(Date:11/14/2019)... ... 13, 2019 , ... NDA Partners Chairman Carl Peck, ... and program management executive with more than 33 years of regulatory and product ... as an Expert Consultant. , Robert Peterson has extensive experience in formulating ...
Breaking Biology News(10 mins):
(Date:12/18/2019)... ... December 17, 2019 , ... ... is pleased to announce that it has hired Dr. Alia Orbin, Ph.D., J.D., ... is experienced in the preparation, filing and prosecution of patent applications related to ...
(Date:12/6/2019)... Calif. (PRWEB) , ... December ... ... device manufacturer Vascular Medcure, Inc. has received FDA 510(k) clearance for its ... The company’s early clinical data suggests the CAPERE® offers great benefits for ...
(Date:12/4/2019)... , ... December 03, 2019 , ... Bold Brahim aka ... on his right front leg. After several weeks of medical management, his condition worsened ... of California Equine Orthopedics . Results revealed Jesse had a severe injury to ...
(Date:12/4/2019)... ... 2019 , ... The technology at the heart of Nanopareil revolves ... on the pharmaceutical industry could be massive. , “The pharmaceutical industry really needs this ... South Dakota School of Mines & Technology and one of the researchers to ...
Breaking Biology Technology:
Cached News: